Nitric oxide-related pathways (NO pathways)

Nitric oxide-related pathways encompass the biochemical processes involving the production and signaling of nitric oxide (NO), a short-lived gaseous molecule essential for physiological functions such as vasodilation and immune regulation (Abramson, 2008). In the context of osteoarthritis (OA), these pathways are often dysregulated, with inducible nitric oxide synthase (iNOS) producing excessive NO that promotes chondrocyte apoptosis and the degradation of the extracellular matrix (Henrotin et al., 2003). Bionanomatrix-OA (BNM-OA) refers to a therapeutic approach, often utilizing self-assembling peptide nanofibers, designed to modulate these NO-related signals within the joint (Lee et al., 2014). The therapy may function by providing a controlled release of NO to stimulate tissue repair or by interfering with the inflammatory signaling that leads to cartilage loss. Because "Nitric oxide-related pathways" describes a broad network of enzymes and secondary messengers rather than a single protein, it is considered a pathway-level target rather than a specific molecular receptor. Understanding the balance of NO levels is crucial, as low levels can be protective while high levels are often cytotoxic in the osteoarthritic environment (Scher et al., 2007).

Other names

Nitric oxide signalingNO-mediated pathwaysNitric oxide metabolismNitric oxide synthase (NOS) signaling

Modulation of nitric oxide bioavailability through controlled release, synthesis inhibition (e.g., iNOS inhibition), or activation of downstream effectors like soluble guanylate cyclase (sGC).